Stellular Bio
PrivateLast Round
Series B
Nov 4, 2021
Total Funding Raised
$170.13M
Company Overview
Stellular Bio operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a Series B round in November 2021.
Stellular Bio is a biotechnology company that develops a platelet-derived regenerative biologic platform aimed at enhancing the treatment of patients with ocular surface disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stellular Bio Comparables
Compare Stellular Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Claris Bio | 81% | |
| Pandorum Technologies | 77% | |
| Cambium Bio | 77% |
For institutional investors. Book with your work email.
Stellular Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 4, 2021 | ||||
| Grant | Sep 30, 2019 | ||||
| Series A Extension | Sep 9, 2019 | ||||
| Series A | Jun 8, 2017 | ||||
| Seed | Jul 28, 2016 | ||||
Grant | Apr 1, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Stellular Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Nest.Bio | Series A Extension |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Oxford Finance | Series B |
| Ziff Capital Partners | Series B, Series A Extension |
| National Heart, Lung, and Blood Institute | Grant |
| Vivo Capital | Series A |
| K2 HealthVentures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors increased 46% MoM.
- Sep 30, 2019
$56M grant awarded by Public Health Emergency Medical Countermeasures Enterprise.
For institutional investors. Book with your work email.
Stellular Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Stellular Bio's valuation, stock price, and market status.
Is Stellular Bio a public or private company?
Stellular Bio is a private company.
What is the current stock price of Stellular Bio?
Stellular Bio is a private company, so its shares have no public market price. Caplight tracks Stellular Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Stellular Bio worth (valuation)?
Valuation information for Stellular Bio is not publicly available.
Can I buy Stellular Bio stock?
Stellular Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Stellular Bio's last funding round?
Stellular Bio's most recent funding round was Series B on November 4, 2021.
Who are the main investors in Stellular Bio?
Key investors in Stellular Bio include Ziff Capital Partners.
Will Stellular Bio IPO soon?
No public IPO plans have been announced for Stellular Bio.
How can I track Stellular Bio secondary market activity?
Caplight tracks bids, offers, and trades in Stellular Bio's shares on secondary markets.